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Abstract— The insulin sensitivity (IS) of the human body
changes with a circadian rhythm. This adds to the time-
varying feature of the glucose metabolism process and places
challenges on the blood glucose (BG) control of patients
with Type 1 Diabetes Mellitus. This paper presents a Model
Predictive Controller that takes the periodic IS into account,
in order to enhance BG control. The future effect of the IS
is predicted using a machine learning technique, namely, a
customized Gaussian Process (GP), based on historical training
data. The training data for the GP is continuously updated
during closed-loop control, which enables the control scheme to
learn and adapt to intra-individual and inter-individual changes
of the circadian IS rhythm. The necessary state information
is provided by an Unscented Kalman Filter. The closed-loop
performance of the proposed control scheme is evaluated for
different scenarios (including fasting, announced meals and
skipped meals) through in silico studies on simulation models
of Go¨ttingen Minipigs.
Index Terms— Artificial Pancreas, insulin sensitivity, Model
Predictive Control, Gaussian Process.
I. INTRODUCTION
The number of people with diabetes mellitus (DM) world-
wide was estimated to be around 415 million in 2015 and
is predicted to increase to 642 million by the year 2040
[1]. Approximately 10% of them have Type 1 DM (T1DM),
which means they always need exogenous insulin to regulate
their blood glucose (BG). Improper control of their BG
concentration can lead to hyperglycemia (BG > 180 mg/dL),
induced secondary complications, and hypoglycemia (BG <
70 mg/dL) induced by over delivery of insulin that can
lead to life-threatening medical conditions. T1DM patients
usually need to control their BG manually by measuring their
BG concentration several times a day and take meal bolus
insulin infusions to compensate for food intake in addition to
continuous basal rate injections. Developments in continuous
glucose monitoring sensors and insulin pumps, however,
provide the opportunity of achieving improved blood glucose
regulation via closed-loop control, which has been the goal
of artificial pancreas device [2], [3].
The glucose metabolism is subject to multiple influential
factors that change in time (e.g. the quasi-periodic appear-
ance of meals [4], the diurnal insulin sensitivity (IS) changes
[5], and the irregular pattern of exercises [6]), which require
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the adoption of adaptive techniques in glucose regulation. A
number of different controllers have been proposed in the
literature to address these requirements. In [7], the authors
adapted the carbohydrate (CHO) to insulin ratio, which
is used to calculate meal boluses, based on the patient’s
reaction to boluses given during the last days to learn and
adapt to their personal metabolic system to improve the
disturbance rejection against food intake. A similar approach
of run-to-run control was used in [8] to update the basal
infusion rate of patients based on past measurements to
improve the tracking performance and to control the BG
concentration to a tighter zone. In all of these studies, only
a few BG measurements were available during the day. A
Model Predictive Iterative Learning Controller was proposed
in [4] based on continuous glucose measurements to exploit
the periodic appearance of meals to improve the control
performance. The work in [9] updated the basal rate during
night time and the carbohydrate-to-insulin ratio (used to
calculate meal boluses) during the day by using run-to-run
adaptation. A clinical study on pigs, where both insulin
and the counterregulatory hormone glucagon were used in
a Generalized Predictive Control approach, was presented in
[10]. An adaptive controller using Gain Scheduling based
on the BG concentration was developed in [11], whereas in
[12] an estimate of the IS determines which controller was
activated. In [5], the authors included the circadian IS of their
metabolic model into an input constraint of a Model Predic-
tive Controller (MPC) to enhance the control performance.
A review of adaptive controllers for BG regulation, including
Minimum Variance Control, Self-Tuning-Regulators, Linear
Quadratic Regulators and Generalized Predictive Control,
can be found in [13].
In this work, we develop a different adaptive control
approach for glucose regulation. We focus on learning the
effect of the individual’s circadian IS and its changes during
closed-loop control using continuous BG measurements to
improve the tracking performance. We propose a combina-
tion of MPC, Unscented Kalman Filter (UKF) and Gaussian
Process (GP) to learn the effect of the circadian IS rhythm on
the metabolic system and incorporate the information in our
controller. Through continuous learning during closed-loop
control, the proposed controller method adapts to an indi-
vidual. It enables personalized control and aims at solving
the problems arising from large inter-individual and intra-
individual changes in the IS of the glucose metabolism. This
enables us to improve the tracking performance and control
the BG concentration to a tighter zone, which corresponds
to a smaller risk of secondary complications. The obtained
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in silico results on a mathematical model of Go¨ttingen Minip-
igs indicate that the proposed controller is able to compensate
for higher insulin resistance in the morning (known as “dawn
syndrome”) and brings the BG concentrations closer to the
reference before breakfast time. By utilizing a detailed plant
model and the UKF from [14], announced food intakes
do not disturb the proposed learning algorithm. Skipped
meals also do not affect the learning and do not disturb the
controller performance. The time and amount of food intake
can therefore be arbitrary and a fixed eating schedule is not
necessary.
The paper is organized as follows: In Section II we present
the model used for the in silico studies and the controller
design. Section III introduces the proposed control algorithm
including UKF, GP and MPC. In Section IV we present and
analyse the results of the in silico studies. Finally, Section V
provides some concluding remarks.
II. SYSTEM MODELLING
A few models have been proposed in the literature to de-
scribe the glucose metabolism, e.g., the Bergman model [15],
Dalla Man model [16], Hovorka model [17] and Sorensen
model [18]. In [19], the Sorensen model was adapted to
model the metabolic system of Go¨ttingen Minipigs and was
parametrized using data from animal trails. This model in-
cludes a linear parameter dedicated to the IS and thus enables
us to easily incorporate a changing IS in the proposed control
algorithm. Furthermore, the metabolic system of humans and
pigs are quite similar [20] and results obtained with this
model can be migrated to a human glucose metabolic model.
Due to space limitation, we only give a brief description of
the Go¨ttingen Minipig model. For implementation purpose,
the controller is designed based on a linearization of this
model.
A. Nonlinear Go¨ttingen Minipig Model
The Go¨ttingen Minipig model consists of 16 states to
describe 9 different compartments. These compartments are
used to model the glucose, insulin and glucagon concen-
tration in the plasma (heart, brain, lung, kidneys, gut), the
liver and the muscle/adipose tissue. They are interconnected
through the blood stream, which links them to the gastro-
intestinal tract and the subcutaneous insulin injections. The
inputs to the system are subcutaneous insulin u(t) and oral
glucose Doral(t) and the output is the BG concentration y(t)
in the plasma.
In the Go¨ttingen Minipig model, the IS is incorporated
through a linear parameter kIS, which determines the effect
of the insulin concentration in the interstitial space of muscu-
lar/adipose tissue IMI(t) on the glucose concentration in the
intracellular fluid space of muscular/adipose tissue GMI(t)
through
G˙MI(t) = (GMV(t)−GMI(t)) /TGM−kISV IMIIMI(t)/V GMI, (1)
where GMV(t) is the glucose concentration in the vascular
blood space of the muscular/adipose tissue, TGM is a time
constant and V IMI and V
G
MI are the distribution volumes of
Doral(k)
u(k) y(k)
x(k)
ukIS(k)
yref
Fig. 1. Block diagram of the GP-MPC.
insulin and glucose in the interstitial space and intracellular
fluid space of muscular/adipose tissue, respectively. In our
engineering approach, we model the circadian IS of the
glucose metabolism by making the corresponding linear
parameter kIS time-dependent. The circadian rhythm of this
parameter is built on and adapted from the periodic function
obtained in [5] (see Fig. 2D). The modified IS has a nominal
value of 1 mg/(min·mU) with a low of 0.55 mg/(min·mU)
and a high of 1.4 mg/(min·mU). This function will be used
as an example rhythm in the in silico studies. Note that
other periodic functions can also be learned by the proposed
method, which enables the control scheme to adapt to inter-
individual and intra-individual changes.
B. Linearization for Controller Design
A linear model with 12 states is derived by linearizing
and reducing the nonlinear Go¨ttingen Minipig model around
a steady state BG concentration of 110 mg/dL, which is
used in the controller design. The parameter kIS(t) enters
the nonlinear system linearly and effects only one state. We
therefore obtain the following time-varying plant
x˙(t) = A(kIS(t))x(t) +Bu(t)
y(t) = Cx(t)
(2)
where x(t) ∈ R12×1, u(t) ∈ R, y(t) ∈ R,
A(kIS(t)) ∈ R12×12, B ∈ R12×1, C ∈ R1×12 and only one
entry in A(kIS(t)) is time-dependent. The training data for
the GP is derived on basis of the linear time-varying model.
For the MPC design, we fix the IS to its nominal value of
1 mg/(min·mU) to obtain a linear time-invariant plant model.
A detailed description of the linear model and matrices can
be found in the appendix.
III. CONTROLLER DESIGN
The proposed controller utilizes an UKF, a GP and an
MPC to counteract the problems arising from a changing
IS. The UKF observes the states, which are used in the
MPC and in calculating the training data for the GP. The GP
predicts the future influence of the changing IS on the BG
concentration and provides it to the MPC, which calculates
the subcutaneous insulin input u(k). The schematic of the
proposed control scheme is provided in Fig. 1.
A. Unscented Kalman Filter
To estimate the states of the metabolic system, the UKF
from [14] is used. The inputs to the filter are the subcu-
taneous insulin input u(k), the food intake Doral(k) and
the intravenous BG measurement y(k). The model used in
the UKF is a reduced version of the Go¨ttingen Minipig
model that was derived in [21] using model residualization
to neglect unobservable states. To calculate the means and
covariances for the state update in the filter, sigma points
are mapped through the reduced-order nonlinear model. The
posterior mean and covariance are then approximated by a
weighted sample mean and covariance of the posterior sigma
points, respectively. The effect of food intake, through the
gastro-intestinal tract, on the metabolic system is incorpo-
rated in the UKF through a feed-forward block. In particular,
the gastro-intestinal tract is modelled by coupled linear first-
order ordinary differential equations [17]:
Ting,1 · M˙Ging,1(t) = Doral(t)−MGing,1(t)
Ting,2 · M˙Ging,2(t) =MGing,1(t)−MGing,2(t)
Doral(t) = doral · δ(t)
rGGA(t) = fG ·MGing,2(t)
(3)
with time constants Ting,1 and Ting,2, the bioavailability of
glucose fG, the glucose amount doral and the states MGing,1(t)
and MGing,2(t) modelling the solid phase of the glucose mass
flow in the stomach and the liquid phase in the intestine,
respectively. The input to this subsystem is the announced
exogenous glucose input Doral(t) and the output of this
system is the glucose appearance rate in the blood stream
rGGA(t). By including this gastro-intestinal tract model in
the UKF, the state estimate provides the MPC with the
information of an exogenous glucose disturbance and it
can therefore counteract the food intake by increasing the
amount of insulin infusion. Including the exogenous glucose
input also enables one to attenuate meal-induced disturbances
when learning the individual’s circadian IS rhythm.
B. Gaussian Process
A GP is a machine learning technique that can be used
to predict future values of a process based on training data
derived from historical measurements. It provides the user
with an expected value and higher moments of the prediction.
The core element of a GP is its kernel function. There
exist a variety of standard kernel functions in the literature,
each with its own purpose. The space of kernel functions
is closed under multiplication so we can obtain customized
kernel functions by multiplying them [22]. In [23], a GP was
used to predict future disturbances of a telescope mount to
include these predictions in an MPC to improve the control
performance. Following a similar approach, the GP in this
paper is used to predict the future impact of the time-varying
IS on the BG concentration.
1) Periodic Kernel Function: The kernel function used in
this paper combines a squared exponential kernel function
kSE(t, t
′; lSE) and a periodic kernel function kP(t, t′; lP, λ):
kSE(t, t
′; lSE) = exp
(−(t− t′)2/2l2SE) (4)
kP(t, t
′; lP, λ) = exp
(
−2 sin2
(pi
λ
(t− t′)
)
/l2P
)
. (5)
The periodic part enables us to predict the periodic IS into
the future, while the squared exponential part provides the
possibility to relax the assumption of perfect periodicity. The
resulting kernel function kC(t, t′;η) is given by
kC(t, t
′;η) = θ2 · kSE(t, t′; lSE) · kP(t, t′; lP, λ) (6)
and has 4 hyperparameters, which are lumped in a vector
η := [θ2, lSE, lP, λ]. Amongst these, θ2 is the variance, lSE
enables us to tune the decaying trust in past training data, lP
is a length-scale and λ is the periodic-length of the training
data. The hyperparameters θ and lP are tuned on the training
data by maximizing the marginal likelihood
log p(y|X,η) = −1
2
yTK(η)−1y−1
2
logK(η)−n
2
log 2pi,
(7)
where y are training data points from the training data set
X , K(η) is the kernel function kC(η) evaluated at the time
stamps of y and n is the number of training points. The initial
values for the optimization are important, because fitting
the hyperparameters is a non-convex optimization problem.
They are chosen as σ = 1 mg/dL and lP = 1, while
λ = 24 · 60 min = 1440 min and lSE = 109 min are
fixed. The parameter lSE is chosen large to have no decay
of trust in the training data as they are derived from the last
2.5 days.
2) Generating the Training Data: The training data for
the GP are obtained during closed-loop control and are
updated every time a new BG measurement is available. The
training data reflects the difference of the changing IS from
its nominal value and its effect on the BG concentration. We
model this effect as a disturbance acting on a linear time-
invariant plant with nominal IS. The training data consist of
this disturbance signal and the corresponding time stamps.
To model the influence of the changing IS as a disturbance,
we separate the system matrixA(kIS(t)) into a time-invariant
part Aˆ and a time-varying part AkIS(t):
x˙(t) = A(kIS(t))x(t) +Bu(t)
= Aˆx(t) +AkIS(t)x(t) +Bu(t).
(8)
Here, Aˆ models the dynamics for the nominal IS of
kIS,nom = 1 mg/(min·mU) and AkIS(t) incorporates the
dynamics due to the difference from the nominal IS. We
then model AkIS(t)x(t) as an IS-inducted disturbance ukIS(t)
entering the system through BkIS :
x˙(t) = A(kIS(t))x(t) +Bu(t)
= Aˆx(t) +Bu(t) +BkISukIS(t).
(9)
The vectorBkIS has only one non-zero entry, becauseAkIS(t)
has only one non-zero entry. This entry links the insulin
concentration in the interstitial of the muscular/adipose tissue
to the change in BG concentration in the intracellular fluid
space of muscular/adipose tissue (see (1)). To generate the
training data, we discretize the system in (9) with a sampling
time of 5 minutes and obtain:
xk+1 = Aˆdxk +Bduk +B
kIS
d u
kIS
k . (10)
We introduce the notation [·]i to refer to the ith row of
a vector/matrix variable and denote [x]i∗ as the row in x
corresponding to the BG concentration in the vascular blood
space of muscular/adipose tissue. At every time step, we
calculate the IS-inducted disturbance using:
ukISk−1 =
(
[xk]i∗ −
[
Aˆdxk−1
]
i∗
− [Bduk−1]i∗
)
/
[
BkISd
]
i∗
.
(11)
Through utilization of the UKF, which includes a model of
the gastro-intestinal tract, food intake does not perturb our
training data, if the food intake is correctly announced. The
time of the food intake can therefore be arbitrary and the
controller does not expect the same meal on the next day
and will not give insulin even though it might not be needed.
Once the training data are computed, they are collected and
used to train the GP. At each time instant, the GP is trained
using training data of multiple days, which has a filtering
effect. Before performing the hyperparameter optimization
on the training data, we apply a zero-phase filter. This filter
erases noise and outliers in the training data, but prevents a
phase shift so the calculated disturbance stays in phase with
the metabolic process.
C. Model Predictive Controller
We use an MPC to calculate the insulin input u in terms
of the amount of insulin units [U] delivered during each
sample period (namely, 5 minutes). The information of the
predicted disturbance from the GP is incorporated in the
MPC’s optimization problem. We use GP-MPC to denote
the MPC using the information provided by the GP and will
refer to the controller without the additional information as
MPC.
The GP-MPC and MPC both use the linear model in (10)
that describes the plant around the linearization point and
calculates the difference of the insulin injection from the
basal value ubasal that is used for the linearization. We limit
our input to be positive, because we can not retrieve insulin
from the body and the counterregulatory hormone glucagon
is not used in this control approach. The prediction of the
future influence of the changing IS, which is provided by the
GP, is incorporated into the system model as a disturbance
ukISk . At time step t, we solve the following optimization
problem using the Yalmip toolbox for Matlab [24]:
J∗0→N−1(x0) = min
U0→N−1
J0→N−1(x0,U0→N−1)
s.t. xk+1 = Aˆdxk +Bduk +BkISd u
kIS
k , x0 = x(t)
yk = Cdxk, yN = 0
0 ≤ uk + ubasal ≤ umax
(12)
where the cost function is
J0→N−1(·, ·) =
N−1∑
k=0
yTk Qyk+(uk−ussk )TR(uk−ussk ). (13)
Note that we introduce the vector uss in the cost function to
reject the disturbance ukIS . ussk is the input that is needed to
reject the disturbance ukISk at steady state and is calculated
by solving the linear equations[
Aˆd − I Bd
Cd 0
] [
xssk
ussk
]
=
[−BkISd ukISk
0
]
(14)
∀k ∈ [0, N − 1]. After solving the optimization problem in
(12), the first element of the input sequence U0→N−1 is
used and the optimization is repeated in a receding horizon
manner every 5 minutes.
The MPC is parametrized with N = 30, Q = 1 and
R = 40000. The prediction horizon is designed by consider-
ing the trade-off between calculation time of the optimization
problem and the accuracy of the model prediction in the
MPC. A longer control horizon would include more of
the system dynamics, but would enlarge the number of
decision variables in the optimization problem of the MPC.
The control weight R is tuned for tracking performance
and disturbance rejection. The design criteria is to have an
undershoot after a food intake of 90g CHO of less than
10 mg/dL. At the same time the weight on the control input
is supposed to lead to a controller that does not react too
aggressively and does not overdose the patient with insulin,
which could induce hypoglycemia. An upper bound umax on
the insulin input of 0.5 U is introduced for the same reason.
Also note, that to prevent insulin overdosing the linear 12
state model used in the MPC has 4 states, which keep track of
the insulin in the body and its effect on the BG concentration.
IV. RESULTS
The nonlinear time-varying Go¨ttingen Minipig model de-
scribed in Section II is used to conduct in silico studies to
validate the effectiveness of the proposed GP-MPC. We use
the model parameters of Minpig 1 from [20], which has a
basal insulin injection of ubasal = 0.169 U per sample-period.
We first simulate fasting conditions in Subsection IV-A to
show that the GP-MPC has improved tracking performance
over the MPC. We then consider the effect of announced
meals in Subsection IV-B. For illustration purposes, we
consider one meal a day and simulate announced meals of
50g CHO at 07:00h everyday to show that the GP-MPC is
insensitive to food intake. Finally, we analyse the effects of a
skipped meal in Subsection IV-C to show that the GP-MPC
is insensitive to changes in the amount or time of food intake.
In each case, the simulation is performed for 7 days and the
GP is activated after 2.5 days when enough training data is
collected during closed-loop control, which is indicated by
a vertical red dashed line in the figures. The statistics, for
GP-MPC and MPC, are calculated using the data from that
point onwards in time.
The obtained results are provided in Figs. 2-4. In these
figures, panels A and C show the closed-loop behaviour
for the MPC and GP-MPC for a period of 7 days. In
panels B and D we show a close-up of Day 5 to analyse
the control behaviour over one day. Panels A and B show
the BG concentration, while panels C and D show the
insulin injection. The yellow and green areas in panels A
and B are the “Safe Zone” and “Tight Zone”, which are
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Fig. 2. Fasting during closed-loop control with GP-MPC and MPC;
circadian IS rhythm in panel D.
defined as [70, 180] mg/dL and [80, 140] mg/dL, respectively.
The reference for the controllers is a BG concentration of
110 mg/dL and the goal is to keep the BG in the “Tight Zone”
to prevent hypoglycemia and hyperglycemia. The statistic
results of the simulations can be found in Table I.
A. Fasting
The fasting scenario in Fig. 2 shows the improved tracking
performance of the GP-MPC in comparison to the MPC.
Once enough training data is collected and the GP is ac-
tivated, a reduction in tracking error can be observed. The
mean BG concentration drops to 110.8 mg/dL in comparison
to 120.5 mg/dL with the MPC. The standard deviation is also
reduced, from 17.3 mg/dL to 4.6 mg/dL, and the GP-MPC
is able to keep the BG in the “Tight Zone” at all times,
whereas the MPC is controlling the BG concentration to the
“Tight Zone” only 75.9% of the time. The BG concentration
at 07:00h in the morning is 110.4 mg/dL and closer to the set
point than during control with the MPC where it is outside
the “Tight Zone” at 145.3 mg/dL. Therefore the GP-MPC
outperforms the MPC during breakfast time. In Fig. 2D one
can see how the controller is counteracting the changing IS.
The insulin input of the GP-MPC (blue line) reacts inverse to
the IS to compensate for the changes in the effectiveness of
the insulin. Also note, that the insulin input of the GP-MPC
decreases or increases before the IS changes, because the GP
provides the MPC with a preview of the upcoming changes
in the IS. For example, the insulin input is decreased by the
GP-MPC around 19:00h to reduce the insulin in the body,
because its effectiveness is going to increase from 22:00h
onwards. This means the proposed control algorithm acts
on the periodic behaviour predictively and does not only
react to a difference between reference and measured BG
concentration, like the MPC does.
B. Announced Meals
To show that the proposed control algorithm can reject
disturbances (like meals) and that the training data calcu-
lation together with the GPs predictions are not disturbed
by food intake, we analyse the control behaviour in the
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Fig. 3. Announced meals during closed-loop control with GP-MPC and
MPC.
presence of announced meals. The amount of CHO and
the time of food intake is announced to the UKF so the
food intake can be included in the state estimation. Fig. 3
shows that the food intake leads to a rapid rise in the BG
concentration which needs to be reduced by increasing the
insulin injection. For the MPC controller, the food intake
raises the BG concentration out of the “Safe Zone” and
therefore causes hyperglycemia during 3.8% of the time.
This is due to the high BG concentration at the time of food
intake. Under control of the GP-MPC the BG concentration
also has a peak, but due to the lower BG concentration at
the time of food intake, there is no hyperglycemic event.
The GP-MPC brings the BG concentration to the “Tight
Zone” within less than two hours and the BG concentration
around lunch time is also more desirable as compared to
that of the MPC, because a lunch would again introduce a
large peak in the BG concentration. Overall the GP-MPC
profits from the better tracking performance with mean and
standard deviation at 112.7 mg/dL and 9.9 mg/dL (against
123.8 mg/dL and 23.0 mg/dL for the MPC) and has improved
%-time in the “Tight Zone” with 95.6% for the GP-MPC vs
71.3% for the MPC. The results for the BG concentration
at 07:00h are comparable to the fasting condition as the last
meal has been digested by that time.
C. Skipped Meals
We will now present the GP-MPC’s reaction to a skipped
meal to show that the training data calculation is not dis-
turbed by food intake. To do this, we simulate a skipped meal
on the 5th day, which is marked with the orange triangle in
Fig. 4. The BG concentration around that time is not lowered
by the GP-MPC, which means that the GP is not predicting
a food intake. Slight changes in BG concentration occur due
to the changing IS (see Fig. 2D). This confirms that the
amount and time of food intake can be arbitrary and do
not alter the improvements in tracking performance of the
GP-MPC in comparison to the MPC. This is also comfirmed
by observing the mean BG concentration of 122.2 mg/dL,
standard derivation of 9.2 mg/dL and %-time in the tight
TABLE I
STATISTICS OF THE in silico STUDIES.
mean BG ± SD %-time %-time %-time %-time BG at 07:00h
(mg/dL) < 70 mg/dL [70− 180] mg/dL [80− 140] mg/dL > 180 mg/dL (mg/dL)
Fasting MPC 120.5 ± 17.3 0 100 75.9 0 145.3GP-MPC 110.8 ± 4.6 0 100 100 0 110.4
Announced MPC 123.8 ± 23.0 0 96.2 71.3 3.8 145.3GP-MPC 112.7 ± 9.9 0 100 95.6 0 110.3
Skipped MPC 123.0 ± 21.8 0 97.2 72.5 2.9 145.3GP-MPC 112.2 ± 9.2 0 100 96.5 0 110.3
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Fig. 4. Announced meals with a skipped meal (marked with triangle)
during closed-loop control with GP-MPC and MPC.
range of 96.5%, which differ only slightly from the results
obtained in Subsection IV-B, caused by the missing peak of
the skipped meal on the 5th day.
V. CONCLUSION
In this work, a GP-MPC is proposed to counteract the
problems arising from a changing IS. By utilizing a GP
together with an UKF and an MPC, the proposed control
algorithm is able to learn the effect of the individual’s
circadian IS rhythm during closed-loop control and is able
to adapt to intra-individual changes of the metabolic system.
The GP-MPC has a better tracking performance than the
MPC and is insensitive to food intake, which therefore allows
flexibility in choosing meal times and amounts.
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APPENDIX
Here, we provide more details on the linear time-varying
model in (2). The input u(t) [U] to the system is the
subcutaneous insulin injection per sampling period. The
output is the plasma glucose concentration [mg/dL]. The
states of the 12 state linear time-variant model are: plasma
glucose concentration [mg/dL], liver glucose concentration
[mg/dL], glucose concentration in the vascular blood space
of the muscle/adipose tissue [mg/dL], glucose concentration
in the intracellular fluid space of the muscle/adipose tissue
[mg/dL], insulin concentration in the interstitial space of
muscle/adipose tissue [mU/L], normalized glucagon con-
centration in the liver [1], glucagon reduction/dissociation
rate [1], normalized insulin concentration in the liver [1],
non-monomeric (inactive) subcutaneous insulin [mU/min],
monomeric (active) subcutaneous insulin [mU/min], glucose
mass flow in the stomach [mg/min] and liquid phase in the
intestine [mg/min]. The system matrices in (2) are:
A(kIS(t)) =

−1.14 0.494 0.647 0 0 0 0 0 0 0 0.0178 0
3.68 −4.56 0 0 −0.018 86.5 −96.8 59.3 0 −0.073 0 0
2.01 0 −3.3 1.3 0 0 0 0 0 0 0 0
0 0 0.2 −0.2 −0.1 · kIS(t) 0 0 0 0 0 0 0
0 0 0 0 −0.0697 0 0 0 0 0.0973 0 0
−0.0018 0 0 0 −6.7 · 10−4 −0.371 0 0 0 −0.00272 0 0
0 0 0 0 0 0.00687 −0.0154 0 0 0 0 0
0 0 0 0 −2.08 · 10−4 0 0 −0.04 0 −8.42 · 10−4 0 0
0 0 0 0 0 0 0 0 −0.0166 0 0 0
0 0 0 0 0 0 0 0 0.015 −0.015 0 0
0 0 0 0 0 0 0 0 0 0 −0.027 0.027
0 0 0 0 0 0 0 0 0 0 0 −0.017

,
B =
[
0 0 0 0 0 0 0 0 2.23 0.99 0 0
]T
, C =
[
1 0 0 0 0 0 0 0 0 0 0 0
]
.
